Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Acquisition Of Cell Design: The Next Logical Step

Executive Summary

Already partnered with Kite to apply two technology platforms to CAR-T candidates, Cell Design adds to Gilead's immuno-oncology expertise. Analysts expect more add-ons for Gilead's increasing IO focus.

Advertisement

Related Content

Milligan’s Retirement Means New CEO For New Gilead
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began
Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground
Deals Of The Year: Cast Your Vote For Top M&A Of 2017
Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel